Heart diseases

XyloCor Therapeutics Commences Phase 2 Component of Phase 1/2 EXACT Clinical Study of XC001 Gene Therapy for Refractory Angina

Retrieved on: 
Tuesday, July 27, 2021
Cardiology, Biotechnology, Pharmaceutical, Surgery, Health, FDA, Genetics, Clinical trials, Medical specialties, Circulatory system, Cardiac surgery, Clinical medicine, Coronary artery bypass surgery, Angina, Coronary arteries, Heart diseases, Cardiogenesis Corporation, Coronary artery disease, XC001, the EXACT Study, Chronic Refractory Angina, XyloCor, XC001, THE EXACT STUDY, CHRONIC REFRACTORY ANGINA, XYLOCOR

XyloCor also confirms that it plans to submit an additional Phase 2 clinical study to the U.S. Food and Drug Administration (FDA) for XC001 as adjunctive therapy to coronary artery bypass grafting (CABG) in 2H21.

Key Points: 
  • XyloCor also confirms that it plans to submit an additional Phase 2 clinical study to the U.S. Food and Drug Administration (FDA) for XC001 as adjunctive therapy to coronary artery bypass grafting (CABG) in 2H21.
  • It is very exciting to now move forward with exploring XC001s potential in the Phase 2 portion of EXACT as a one-time therapy for patients with refractory angina.
  • XyloCor commenced the EXACT Trial, a Phase 1/2 study of XC001 in chronic refractory angina, in 2020.
  • The Epicardial Delivery of XC001 Gene Therapy for Refractory Angina Coronary Treatment (EXACT) clinical trial is a Phase 1/2 multicenter, open-label, single-arm, dose-escalation trial.

Axon Therapies Announces Chad Hoskins As Chief Executive Officer

Retrieved on: 
Wednesday, July 21, 2021
Branches of biology, Anatomy, Heart diseases, Organ failure, Axon Enterprise, Taser, Axon, Heart failure, Hoskins

SANTA CLARA, Calif., July 21, 2021 /PRNewswire/ -- Axon Therapies, a private company focused on addressing a root cause of heart failure, today announced the appointment of seasoned medical device executive Chad Hoskins as Chief Executive Officr (CEO).

Key Points: 
  • SANTA CLARA, Calif., July 21, 2021 /PRNewswire/ -- Axon Therapies, a private company focused on addressing a root cause of heart failure, today announced the appointment of seasoned medical device executive Chad Hoskins as Chief Executive Officr (CEO).
  • "Axon is poised to disrupt the heart failure market by treating a root cause of the disease rather than simply addressing patient symptoms.
  • Mr. Hoskins joins Axon with more than two decades of experience bringing innovative medical technologies to market.
  • SAVM is an incredibly novel approach that aims to rebalance blood volume, reduce congestion and stop the progression of heart failure, all without the need of additional drugs or implantable devices" stated Chad Hoskins, CEO of Axon Therapies.

Ancora Heart Secures $80 Million in Financing

Retrieved on: 
Monday, July 19, 2021
Surgery, Medical devices, Hospitals, Clinical trials, Cardiology, Biotechnology, Other Health, Health, General Health, Anatomy, Branches of biology, Organs anatomy), Heart diseases, Cardiovascular physiology, Ejection fraction, Heart failure, Ventricle, Heart, the AccuCinch Ventricular Restoration System and the CORCINCH Studies, Ancora Heart, THE ACCUCINCH VENTRICULAR RESTORATION SYSTEM AND THE CORCINCH STUDIES, ANCORA HEART

Ancora Heart, Inc ., a company developing a novel therapy to address heart failure, today announced it has closed an $80 million equity financing.

Key Points: 
  • Ancora Heart, Inc ., a company developing a novel therapy to address heart failure, today announced it has closed an $80 million equity financing.
  • Ancora Heart is at an exciting stage as we continue with our pivotal clinical trial to support our PMA submission to the FDA, and this investment will help us prepare for potential launch and subsequent commercialization, said Jeff Closs, president and CEO of Ancora Heart.
  • About half of HF patients have heart failure with a reduced ejection fraction (HFrEF) and an enlarged left ventricle, the main pumping chamber of the heart, which causes more stress on the heart and leads to reduced pumping efficiency.
  • (ClinicalTrials.gov Identifier: NCT03183895 )
    Ancora Heart is a medical device company dedicated to providing new treatment options for people with heart failure (HF).

Canon Medical Partners with Cleerly to Tackle Heart Disease, the Leading Cause of Death

Retrieved on: 
Friday, July 16, 2021
Oncology, Health, Medical devices, Technology, Other Technology, Radiology, Cardiology, Medicine, Heart diseases, Heart, Organs, Branches of biology, Coronary artery disease, Disease, Articles, Canon Medical Systems USA, Inc., Canon Medical Systems Corporation, Cleerly, CANON MEDICAL SYSTEMS USA, INC., CANON MEDICAL SYSTEMS CORPORATION, CLEERLY

Together, the companies aim to support broader adoption of cardiac CT for the diagnosis and triage of heart disease.

Key Points: 
  • Together, the companies aim to support broader adoption of cardiac CT for the diagnosis and triage of heart disease.
  • In addition, a heart attack or death is often the first symptom of heart disease in more than 50% of individuals diagnosed with coronary artery disease.
  • Once again, Canon has harnessed its strengths and expertise to address pressing healthcare problems, such as heart disease, says Yuji Hamada, president and CEO, Canon Medical Systems, USA.
  • At Canon Medical, we work hand in hand with our partners - our medical, academic and research community.

Tenaya Therapeutics Unveils Preclinical Research Supporting Product Candidate for Rare and Prevalent Heart Disease Indications at ESC Heart Failure 2021

Retrieved on: 
Tuesday, July 13, 2021
Biotechnology, General Health, Health, Pharmaceutical, Cardiology, Heart diseases, Anatomy, Cardiomyopathy, Heart failure with preserved ejection fraction, Medical specialties, Heart failure, Branches of biology

We are very encouraged by the preclinical data that supports the potential multi-modal benefit of TYA-11631 in HFpEF, one of the greatest areas of unmet need in heart disease, said Faraz Ali, Chief Executive Officer of Tenaya Therapeutics.

Key Points: 
  • We are very encouraged by the preclinical data that supports the potential multi-modal benefit of TYA-11631 in HFpEF, one of the greatest areas of unmet need in heart disease, said Faraz Ali, Chief Executive Officer of Tenaya Therapeutics.
  • Tenaya has established more than 40 in-house hiPSC-CM disease models and is pursuing more targets identified through ongoing screening efforts.
  • Tenaya Therapeutics is a biotechnology company committed to a bold mission: to discover, develop and deliver curative therapies that address the underlying drivers of heart disease.
  • Tenaya is developing therapies for rare genetic disorders as well as for more prevalent heart conditions through three distinct but interrelated product platforms: Gene Therapy, Cellular Regeneration and Precision Medicine.

Breakthrough results for empagliflozin confirm EMPEROR-Preserved as first and only successful trial for heart failure with preserved ejection fraction

Retrieved on: 
Tuesday, July 6, 2021
Science, Cardiology, Biotechnology, Research, Pharmaceutical, Health, Diabetes, Clinical trials, Heart diseases, Anti-diabetic drugs, Medical specialties, Anatomy, Circulatory system, Glucosides, SGLT2 inhibitors, Boehringer Ingelheim, Empagliflozin, Heart failure with preserved ejection fraction, Heart failure, Ejection fraction

When added to the EMPEROR-Reduced trial results, these findings demonstrate empagliflozins efficacy in all forms of heart failure regardless of ejection fraction.

Key Points: 
  • When added to the EMPEROR-Reduced trial results, these findings demonstrate empagliflozins efficacy in all forms of heart failure regardless of ejection fraction.
  • HFpEF has long been the most challenging form of heart failure to treat, said Professor Stefan Anker, Heart Failure Cardiologist at Charit Berlin, Germany, and EMPEROR-Preserved Principal Investigator.
  • Building on previous results from the EMPA-REG-OUTCOME trial, and the EMPEROR-Reduced trial in heart failure with reduced ejection fraction, the EMPEROR-Preserved findings demonstrate that empagliflozin reduces cardiovascular death or hospitalization for heart failure and has the potential to transform the care of people living with heart failure.
  • With the earlier EMPEROR-Reduced trial results, we are confident in the potential of empagliflozin to positively impact the lives of adults across the full spectrum of heart failure.

Sequana Medical’s results from RED DESERT alfapump DSR® study presented as one of the Highlights at Heart Failure 2021 Online Congress

Retrieved on: 
Tuesday, July 6, 2021
Organ failure, Heart diseases, Branches of biology, Medical specialties, Acute decompensated heart failure, Hypervolemia, Heart failure, Biology

alfapump DSR combines DSR therapy with the proven alfapump to deliver a fully implanted system for long-term DSR therapy.

Key Points: 
  • alfapump DSR combines DSR therapy with the proven alfapump to deliver a fully implanted system for long-term DSR therapy.
  • Strong top-line results from the RED DESERT study showed that repeated dose alfapump DSR therapy in diuretic-resistant heart failure patients is highly effective at managing the fluid and sodium balance and improves cardio-renal status.
  • Sequana Medical has combined its proven alfapump and proprietary DSR therapy, and is developing the alfapump DSR, a breakthrough approach to fluid overload due to heart failure.
  • The SAHARA DESERT study of alfapump DSR in decompensated heart failure patients is ongoing.

Scan an Entire Heart in 1-2 Heartbeats - Modern Heart and Vascular Institute

Retrieved on: 
Monday, July 5, 2021
Circulatory system, Cardiovascular system, Medical specialties, Heart diseases, Aging-associated diseases, Peripheral artery disease, Coronary artery disease, Heart failure, Artery, Heart, Interventional radiology, Cardiovascular disease in Australia

The providers at Modern Heart and Vascularperformthese extensive diagnostic tests in an outpatient setting to avoid the need for invasive testing.

Key Points: 
  • The providers at Modern Heart and Vascularperformthese extensive diagnostic tests in an outpatient setting to avoid the need for invasive testing.
  • To learn more about cardiac computed tomography (CT) at Modern Heart and Vascular Institute, please click here .
  • Modern Heart and Vascular Institute assists with variousheart & vascular symptoms & issues such as chest pain, high cholesterol, congestive heart failure, peripheral arterial disease (PAD), arrhythmia, coronary artery disease, high blood pressure and much more.Modern Heart and Vascular specializes in all aspects of cardiovascular and metabolic diseases.
  • For comprehensive cardiovascular care, contact Modern Heart and Vascular Institute by phone or online today.

scPharmaceuticals Inc. Announces Receipt of Written Minutes from Type C Meeting with the FDA Regarding Development of FUROSCIX®

Retrieved on: 
Thursday, July 1, 2021
Heart diseases, Organ failure, Asset, Cash, Cash and cash equivalents, Heart failure, Traffic congestion, Congestion, Branches of biology, Human activities, Human behavior

We are pleased with the outcome of our Type C meeting, and subsequent receipt of the meeting minutes, as this represents an important step forward as we continue to advance FUROSCIX toward potential commercialization, stated John Tucker, chief executive officer of scPharmaceuticals.

Key Points: 
  • We are pleased with the outcome of our Type C meeting, and subsequent receipt of the meeting minutes, as this represents an important step forward as we continue to advance FUROSCIX toward potential commercialization, stated John Tucker, chief executive officer of scPharmaceuticals.
  • The results, if positive, can potentially demonstrate significant cost savings from treating congestion in patients with heart failure with FUROSCIX outside of the hospital setting.
  • scPharmaceuticals ended the first quarter of 2021 with cash, cash equivalents, restricted cash and investments of $96.5 million.
  • FUROSCIX has the potential to provide an outpatient alternative for the treatment of worsening heart failure due to congestion.

What is the Silent Killer? It's High Blood Pressure - Interview With Dr. Rajiv Agarwal

Retrieved on: 
Wednesday, June 30, 2021
Circulatory system, Cardiovascular system, Anatomy, Aging-associated diseases, Heart diseases, Cardiovascular physiology, Angiology, Hypertension, Cardiology, Coronary artery disease, Peripheral artery disease, Heart failure

HOUSTON, June 30, 2021 /PRNewswire/ -- In this interview, Dr. Rajiv Agarwal , board-certified cardiologist at Modern Heart and Vascular Institute , talked about how understanding blood pressure can help prevent heart attacks and strokes.

Key Points: 
  • HOUSTON, June 30, 2021 /PRNewswire/ -- In this interview, Dr. Rajiv Agarwal , board-certified cardiologist at Modern Heart and Vascular Institute , talked about how understanding blood pressure can help prevent heart attacks and strokes.
  • Dr. Agarwal talked about the importance of diagnosing symptoms of high blood pressure, causes and treatments to help patients.With a focus on prevention, there are many steps people can take to control hypertension.
  • To learn more about high blood pressure, please click here .
  • Modern Heart and Vascular Institute assists with variousheart & vascular symptoms & issues such as chest pain, high cholesterol, congestive heart failure, peripheral arterial disease (PAD), arrhythmia, coronary artery disease, high blood pressure and much more.